US · Healthcare · Biotechnology
EPS came in at 1.71 against a street estimate of -0.39 — a beat of 538.5%.
Analysts rate MeiraGTx Holdings PLC a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $29.43.
| Fund | Stake |
|---|---|
| Sanofi | 12.70% |
| Perceptive Advisors LLC | 11.23% |
| Rubric Capital Management LP | 7.29% |
| Johnson & Johnson | 6.91% |
| Adage Capital Partners Gp LLC | 4.58% |
| Opaleye Management Inc | 3.70% |
| BlackRock Inc | 3.30% |
| Millennium Management LLC | 3.09% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 MEIRAGTX HOLDINGS PLC – Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and cash equivalents increased to $143.2 million as of June 30, | 2026-08-13 |
| Results announced · Q3 2026 MEIRAGTX HOLDINGS PLC – Q2 2026 FINANCIAL & OPERATIONAL SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $143.2 million as of June 30, 2026 (vs | 2026-08-13 |
| Material agreement · Q2 2026 MEIRAGTX HOLDINGS PLC – FORM 8-K SUMMARY As of June 30, 2026 --- HEADLINE NUMBERS • Royalty Note financing: Up to $375 million in total commitments | 2026-07-07 |
| Shareholder vote results · Q2 2026 MEIRAGTX HOLDINGS PLC – DOCUMENT SUMMARY HEADLINE NUMBERS • Annual General Meeting held on June 11, 2026 • 75,326,022 ordinary shares present in per | 2026-06-15 |
| Quarterly report · Q1 2026 MEIRAGTX HOLDINGS PLC - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash position: $71.5 million at March 31, 2026 (up from $65.9 million at December 31, 202 | 2026-05-14 |
| Results announced · Q2 2026 MEIRAGTX Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net loss for Q1 2026: $46.3 million ($0.57 per share) vs. $40.0 million ($0.51 per | 2026-05-14 |
| Proxy statement · Q2 2026 MEIRAGTX HOLDINGS PLC – 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGE • CEO total compensation figure not disclosed in provided document ex | 2026-04-30 |
| Annual report FY2025 MEIRAGTX HOLDINGS PLC – 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Market capitalization: $524.5 million (as of June 30, 2025) • Outstanding shares: | 2026-03-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Strategic collaboration and license agreement with Hologen for gene therapy research MeiraGTx completed a major strategic partnership with Hologen on April 20, 2026. Under this deal, Hologen is committing $200 million upfront to develop and commercialize MeiraGTx's gene ther | 2026-04-24 |
| Acquired gene therapy product asset and license agreement from Janssen MeiraGTx Holdings plc acquired a gene therapy asset from Janssen Pharmaceuticals on April 15, 2026, for treating X-linked retinitis pigmentosa (RPGR). The company paid $25 million upfront an | 2026-04-16 |
| Company repurchases 2.3 million ordinary shares for $18.2 million MeiraGTx Holdings plc repurchased 2.3 million of its own shares from Perceptive Life Sciences Master Fund for $18.2 million at $7.91 per share on December 31, 2025. Perceptive, a major share | 2026-01-02 |
| Strategic collaboration and license agreement with Eli Lilly for genetic medicines MeiraGTx Holdings plc signed a strategic collaboration agreement with Eli Lilly and Company on November 7, 2025, to jointly research, develop, and commercialize genetic medicines for eye dis | 2025-11-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MeiraGTx Holdings PLC — free to start.
Google PlayApp StoreData updated 2026-09-18.